CN101015350A - Senescence delaying health care composition - Google Patents
Senescence delaying health care composition Download PDFInfo
- Publication number
- CN101015350A CN101015350A CNA2007100192957A CN200710019295A CN101015350A CN 101015350 A CN101015350 A CN 101015350A CN A2007100192957 A CNA2007100192957 A CN A2007100192957A CN 200710019295 A CN200710019295 A CN 200710019295A CN 101015350 A CN101015350 A CN 101015350A
- Authority
- CN
- China
- Prior art keywords
- resveratrol
- butein
- fisetin
- quercetin
- health care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a health care composition for delaying senility, which is prepared from the constituents of resveratrol 40-350mg, fisetin 40-350mg, butein 40-350mg, quercetin 70-200mg, phosphatidy lcholine 80-1500mg, phosphoinositide 10-100mg.
Description
Technical field
The present invention relates to a kind of health products, particularly a kind of health composition that delays senility.
Background technology
Before this method invention, cholesterol levels, anti-platelet aggregation, the oxidation of anti-human low density lipoprotein, the research of antitumaous effect aspect that resveratrol is regulated in the blood mainly as estrogen are more, also apply in medicine and the nourishing healthy product simultaneously to sell on market.
Also have with oxidation resistant resveratrol be used for anti-ageing, its, dose was lower than 20mg every day, this is because one be that the resveratrol price is higher, it two is not enough to the characteristic of resveratrol understanding, comprise content big later toxic and side effect have little understanding, so its as anti-ageing thing without any actual effect.With regard to its mechanism, resveratrol is after entering the blood of human body, and the time of stop is very short, and most of horse back is just discharged by urine rapidly, has little time to act on relevant antidotal physiological structure, does not also just have any anti-aging effects.
Summary of the invention
Purpose of the present invention just is to overcome above-mentioned defective, develops a kind of anti-ageing healthcare medicine.
Technical scheme of the present invention is:
The health composition that delays senility, its major technique is characterised in that substantially to be made up of resveratrol, fisetin, butein, quercetin, lecithin, IP6, its compatibility relationship is resveratrol 40～350mg, fisetin 40～350mg, butein 40～350mg, quercetin 70～200mg, lecithin 80～1500mg, IP6 10～100mg.
Its further technical scheme is:
Be that the proportioning between resveratrol, fisetin, the butein is 1: 1: 1.
Though advantage of the present invention and effect are that resveratrol time of staying in human body is short, but after adding quercetin, lecithin, IP6 prolonged its time that stops in human body greatly, thereby give full play to its antidotal effect and effect, and butein, fisetin itself also have function in delaying senility and effect, with the collaborative performance of resveratrol anti-aging effects, effect is more obvious.And, increase Resveratrol content and can't bring toxic and side effect, promptly nontoxic.
The specific embodiment
Embodiment 1:
Get resveratrol 185mg, fisetin 185mg, butein 185mg, quercetin 100mg, lecithin 500mg, IP6 50mg mixes; Can be made into oral liquid, capsule, tablet, granule, pulvis.
Embodiment 2:
Get resveratrol 155mg, fisetin 155mg, butein 155mg, quercetin 120mg, lecithin 800mg, IP6 70mg mixes; Can be made into oral liquid, capsule, tablet, granule, pulvis.
According to experiment showed,, find that resveratrol helps to prolong the life-span of yeast, nematode etc., and find that this composition confrontation mammal also has the remarkable efficacy of " increasing the longevity " by after adding some special compositions and making up.The present invention has mainly used three kinds of compounds: butein, fisetin (, 3,7,3 ', 4 '-four hydroxyls (base) flavones) and resveratrol, discovery can make average life span increase by 31%, 55% and 70%, and these three kinds of materials all can significantly increase the maximum average life span of mammal.
Particularly:
1. increase the dose of every day, it is a lot of that the active ingredient that rests in the blood of human body is increased, and the antidotal active component of acting on of q.s can be arranged.For increasing after the dose to whether toxic effect of human body, by science experiment showed, that we can find, the safe dose of resveratrol is 1000mg/kg every day, is far longer than the dose that we set, and we can say that it is a safety non-toxic.
2. its antidotal effect of single resveratrol is limited after all, by add butein, fisetin (, 3,7,3 ', 4 '-four hydroxyls (base) flavones) these two kinds have the composition of remarkable anti-aging effects to mammal, and the time that the present invention can be delayed senility prolongs more than 60% on the basis of single component, increases effect of the present invention.
3. add the composition of time of staying that to prolong resveratrol in blood.By a large amount of experimental studies and document verification, add quercetin, phosphatide (lecithin), IP6 is called for short IP6 (rice bran extract) the energy significant prolongation holdup time of resveratrol in blood, extend to 4～7 times of former time, so can improve the action time of resveratrol greatly, significantly strengthen the function that the present invention delays senility.
4. after the present invention carries out such combination, can play cooperative effect, rather than simple stack, through relevant experimental study, the present invention can bring into play tangible function in delaying senility, and safe without toxic side effect.
Experimental results show that:
Utilize a kind of compound to increase the life-span of fat mouse, find that this compound has reversed all gene expressions of high caloric diet mouse-wherein have some and diabetes, heart disease and other and all fat relevant diseases, and find that first this micromolecular compound resveratrol (resveratrol) is to mammiferous benefit.
Mouse is divided into three groups: first group gives general diet (being called for short the SD group); Second group of diet that gives high heat, wherein percent 60 of total amount of heat from fat (being called for short the HC group); The 3rd group give with second group of identical food, and add to edible resveratrol (being called for short the HCR group).All mouse all are that about 52 weeks are big when beginning to do experiment, are equivalent to the mankind in middle age.
In 60 weeks when big, HC group and HCR organize mouse survival rate begin difference and keep 3 to 4 months difference.In 114 weeks when big, the HC group has percent 58 death, and HCR group and SD organize and have only percent 42 death.Find that resveratrol can make the death rate of HC group reduce by percent 31, also do not have significantly and increase even compare the death rate with the SD group.(annotate: those mouse all also live, so this also is not last data.) in the middle of to increase be about percent 15 the life-span.We will wait until that all mouse just have exact figure after all dead, and the life-span of this mouse is two-and-a-half years.Therefore last numeral also will wait about 5 months again, but undoubtedly, we have seen that mouse can increase the life-span.
Research finds that also the HCR group has extraordinary physique, the mouse that surpasses the HC group far away in physical stamina test.The mouse of feeding resveratrol is not only long-lived, and their vigor is better.The physical stamina test result proves aging improving.
Resveratrol has the form of two kinds of existence: cis and trans.Naturally occurring resveratrol is generally trans, after trans-resveratrol is absorbed and enters blood of human body, there be not quercetin, phosphatide (lecithin), IP6 is called for short when IP6 (rice bran extract) is common to be existed, in blood, change cis-resveratrol rapidly into, excrete with urine, and the adding quercetin, phosphatide (lecithin), after the common absorption of IP6 abbreviation IP6 (rice bran extract) enters blood, they will suppress trans-resveratrol and change cis-resveratrol into, prolong its time of staying in vivo, give full play to its effect.
Resveratrol (resveratrol, Res), fisetin (fistein), butein (butein) etc. have the effect of stronger anti-oxidant, Green Tea Extract, mainly prolong the life-span of cell by the activity that activates histon deacetylase (HDAC).Res is a kind of Polyphenols chemical substance that produces naturally, extensively is present in some plants, and as grape, berry and peanut, it is a kind of non-flavones polyphenol compound that contains the stilbene class formation, has important biological action.Resveratrol can play the highest activation activity to ySir2 by the Km value that reduces the acetylation substrate, makes its life-span prolong 70%.And resveratrol is when existing jointly with fisetin, butein, and conformation will change when resveratrol combines with the SIRT1 gene, regulates the phase legumin gene of p53-AMC, thereby increases the survival of cell, increases man's lifespan greatly.
The present invention is raw materials used can both to buy from the market, and used resveratrol raw material is a trans-resveratrol.
The claimed description that has scope to be not limited only to the foregoing description of the present invention.
Claims (4)
1. the health composition that delays senility, it is characterized in that forming by resveratrol, fisetin, butein, quercetin, lecithin, IP6 substantially, its compatibility relationship is resveratrol 40～350mg, fisetin 40～350mg, butein 40～350mg, quercetin 70～200mg, lecithin 80～1500mg, IP6 10～100mg.
2. the health composition that delays senility according to claim 1 is characterized in that the proportioning between resveratrol, fisetin, the butein is 1: 1: 1.
3. the health composition that delays senility according to claim 1 and 2 is characterized in that resveratrol 185mg, fisetin 185mg, butein 185mg, quercetin 100mg, lecithin 500mg, IP6 50mg.
4. the health composition that delays senility according to claim 1 and 2 is characterized in that resveratrol 155mg, fisetin 155mg, butein 155mg, quercetin 120mg, lecithin 800mg, IP6 70mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100192957A CN100506088C (en) | 2007-01-12 | 2007-01-12 | Senescence delaying health care composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007100192957A CN100506088C (en) | 2007-01-12 | 2007-01-12 | Senescence delaying health care composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101015350A true CN101015350A (en) | 2007-08-15 |
| CN100506088C CN100506088C (en) | 2009-07-01 |
Family
ID=38724700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007100192957A Expired - Fee Related CN100506088C (en) | 2007-01-12 | 2007-01-12 | Senescence delaying health care composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100506088C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009082459A2 (en) * | 2007-12-24 | 2009-07-02 | Natrol, Inc. | Anti-aging composition containing resveratrol and method of administration |
| WO2015057726A1 (en) * | 2013-10-14 | 2015-04-23 | Biomarker Pharmaceuticals, Inc. | Nutrient combinations for affecting an aging process |
| CN109700790A (en) * | 2018-12-28 | 2019-05-03 | 中南大学湘雅医院 | A kind of anti aging effect drug Butein targeting AQP3 |
| CN110075103A (en) * | 2019-06-06 | 2019-08-02 | 中国科学院动物研究所 | The purposes of Quercetin |
| CN110237057A (en) * | 2018-03-07 | 2019-09-17 | 中国科学院上海生命科学研究院 | Application of the inositol in anti-aging |
| CN110251527A (en) * | 2019-06-06 | 2019-09-20 | 泓博元生命科技（深圳）有限公司 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
| CN113384579A (en) * | 2021-06-25 | 2021-09-14 | 王世宣 | Pharmaceutical composition and application thereof in delaying senescence |
-
2007
- 2007-01-12 CN CNB2007100192957A patent/CN100506088C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009082459A2 (en) * | 2007-12-24 | 2009-07-02 | Natrol, Inc. | Anti-aging composition containing resveratrol and method of administration |
| WO2009082459A3 (en) * | 2007-12-24 | 2009-09-17 | Natrol, Inc. | Anti-aging composition containing resveratrol and method of administration |
| WO2015057726A1 (en) * | 2013-10-14 | 2015-04-23 | Biomarker Pharmaceuticals, Inc. | Nutrient combinations for affecting an aging process |
| US9138453B2 (en) | 2013-10-14 | 2015-09-22 | Biomarker Pharmaceuticals, Inc. | Nutrient combinations for affecting an aging process |
| US10016476B2 (en) | 2013-10-14 | 2018-07-10 | Biomarker Pharmaceuticals, Inc. | Nutrient combinations for affecting an aging process |
| CN110237057A (en) * | 2018-03-07 | 2019-09-17 | 中国科学院上海生命科学研究院 | Application of the inositol in anti-aging |
| CN109700790A (en) * | 2018-12-28 | 2019-05-03 | 中南大学湘雅医院 | A kind of anti aging effect drug Butein targeting AQP3 |
| CN110075103A (en) * | 2019-06-06 | 2019-08-02 | 中国科学院动物研究所 | The purposes of Quercetin |
| CN110251527A (en) * | 2019-06-06 | 2019-09-20 | 泓博元生命科技（深圳）有限公司 | The composition of niacinamide-containing mononucleotide is in the application of anti-aging drug/health care product |
| WO2020244249A1 (en) * | 2019-06-06 | 2020-12-10 | 泓博元生命科技（深圳）有限公司 | Application of composition containing nicotinamide mononucleotide in anti-ageing drugs/healthcare products |
| CN110251527B (en) * | 2019-06-06 | 2021-06-25 | 泓博元生命科技（深圳）有限公司 | Application of composition containing nicotinamide mononucleotide in anti-aging drugs/health care products |
| CN113384579A (en) * | 2021-06-25 | 2021-09-14 | 王世宣 | Pharmaceutical composition and application thereof in delaying senescence |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100506088C (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100506088C (en) | Senescence delaying health care composition | |
| CN101632655B (en) | Resveratrol and bioflavonoid nutritional composition for delaying senility | |
| Butnariu et al. | Design management of functional foods for quality of life improvement | |
| KR102299934B1 (en) | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution | |
| US20210085712A1 (en) | Functional food | |
| Mohamadi Saei et al. | Effects of dietary savory and myrtle essential oils on growth, survival, nutritional indices, serum biochemistry, and Hematology of farmed rainbow trout, Oncorhynchus mykiss, fry | |
| JP2020147582A (en) | Composition for arthritis, mobility and delay ageing | |
| CN112367848A (en) | Composition for supporting an animal with cancer | |
| CN105283190A (en) | A marine oil formulation comprising reservatrol or derivatives thereof for use in treating, delaying and/or preventing alzheimer's desease | |
| Aramli et al. | Effect of dietary antioxidant supplements (selenium forms, alpha-tocopherol, and coenzyme Q10) on growth performance, immunity, and physiological responses in rainbow trout (Oncorhynchus mykiss) using orthogonal array design | |
| Anne Rebecca | Growth performance of the freshwater prawn Macrobrachium rosenbergii post larvae fed with Ocimum sanctum (tulsi) and Withania somnifera (ashwagandha) incorporated feeds | |
| CN102847159A (en) | A glucose metabolism enhancer | |
| WO2021203661A1 (en) | Seaweed fruit and vegetable formula for assisting in reducing fat and losing weight | |
| KR101371143B1 (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
| JP2013133310A (en) | Anredera cordifolia mixture and method for producing the same | |
| EP2783684B1 (en) | Prenylflavanone compounds for modulating diabetes | |
| JP2007029020A (en) | Black vinegar health food and method for producing the same | |
| JP2010030950A (en) | Prophylactic and therapeutic agent for metabolic syndrome and functional food | |
| TW201004637A (en) | A food formula to slow the aging process | |
| CN101371827A (en) | Resveratrol composition for delaying age | |
| JP2007297370A (en) | Suppressor of increase in blood glucose level | |
| JP2016040314A (en) | Oral pharmaceutical composition and functional food | |
| CN112690453A (en) | Composition, compound oil and application thereof | |
| KR20150064519A (en) | Composition for anti-fatigue or anti-hangover comprising fermented composition of rhynchosia nulubilis and bamboo salt | |
| CN103355665B (en) | A kind of composition for auxiliary hyperglycemic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090701 Termination date: 20180112 |